In a sleeve gastrectomy (SG, left), about 75% of the stomach is
removed, leaving a small tube, or sleeve that holds less food. In
the Roux-en-Y gastric bypass (RYGB, right), the surgeon divides
the stomach and connects a small piece to the lower part of the small intestine, bypassing the upper intestine. Both procedures lower CVD risk better than nonsurgical treatments, but the RYGB is more effective and produces more durable weight loss and blood sugar control, as well.
More than 10 randomized clinical trials have shown that bariatric surgery—also called weight-loss surgery or metabolic surgery—improves diabetes control and cardiovascular disease (CVD) risk factors better than the best medications in individuals with obesity and type 2 diabetes mellitus (T2DM). “Glucagon-like peptide-1 receptor (GLP-1) agonists and sodium glucose transporter 2 (SGLT2) inhibitors are among the […]
To continue reading this article or issue you must be a paid subscriber. Sign in
